by Truveta staff | Apr 4, 2024 | Data
US spending on medical devices and in-vitro diagnostics totals more than $199 billion a year, with most of the costs associated with clinical development. Label expansion provides a pathway for recouping costs associated with the device development process by...
by Truveta staff | Apr 2, 2024 | Data
A common misconception is that drugs and devices must gain explicit approval from the FDA for each specific use before healthcare providers can employ them. However, a practice known as off-label use challenges this notion, revealing a broader landscape of treatment...
by Truveta staff | Mar 12, 2024 | Data
Stories from women whose endometriosis pain has been dismissed are devastatingly common. A typical woman in the United States will wait 10 years after her symptoms first appear to receive an endometriosis diagnosis. This delay is rooted in a pervasive lack of...
by Truveta staff | Feb 29, 2024 | Data, News, Technology
Healthcare data traditionally has been too siloed, inaccessible, and messy to be useful for research. And one of the biggest challenges has been that critical information about a patient’s health is locked away in the unstructured text in clinician notes. Thanks to...
by Truveta staff | Feb 22, 2024 | Data, Technology
The National Academy of Medicine has estimated that less than half of all medical care in the US is supported by adequate evidence of effectiveness. The proliferation of treatment options in some disease states and the rising costs of many of those treatments have...
by Truveta staff | Feb 1, 2024 | Data
Heart disease is a massive crisis in this country. Ranking as the leading cause of death in the US for more than a century, heart disease takes a life approximately every 33 seconds. That’s about the same time it takes an average person to blink eight times. Although...
